SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
The SAS and AstraZeneca collaboration will enable teams across the organisation to increase clinical research innovation using SAS’s cloud-based software and technologies.
SAS will support the redesign of clinical and patient data flow by delivering analytics and AI, redesigning clinical trials in a fast-evolving regulatory environment, enabling data re-use and assisting with the acceleration of reporting and submission timelines.
The company will also deliver increased capacity, automation, interoperability and flexibility in order to analyse diverse and novel patient data sources as part of the submissions process. These could emerge from wearables, sensors or precision medicine.
This will be achieved by supporting the analysis and reporting phases with SAS Life Science Analytics Framework and SAS Viya – a cloud-based industry platform enabling swift decision-making regardless of data volumes or complexity using modern cloud technologies.
Bryan Harris, SAS executive vice president and chief technology officer, reflected: “I’m delighted that SAS is building on the strong relationship it has had with AstraZeneca over many years by being part of this transformation programme. The work they do positively impacts the lives of millions of people around the world.”
He added: “This is exciting because we have solidified a great foundation between our companies, but we also recognise we are just scratching the surface. We pay attention to technology and the advancements in AI, and we thrive on thinking through how our technology blended with AstraZeneca’s expertise and insight can create new medical solutions for their customers.”
Christopher J Miller, vice president biometrics at AstraZeneca, concluded: “This partnership with SAS supports the transformation of how we use clinical data to support our patient-centric approach and focus on getting medicines to patients faster than ever before.
“It will also allow us to introduce new ways of working and embrace new technologies and trial models to accelerate our portfolio.”
by John Pinching
Source: pharmatimes.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
